Dr Reddy's Laboratories Ltd, a major Indian pharmaceutical company, reported an 86% decline in consolidated profit after tax, amounting to ₹221.3 crore for the fourth quarter ending March 31, 2026. This sharp drop is primarily due to a 51% decrease in sales of generic drugs in North America, where revenue fell to ₹1,756.2 crore from ₹3,558.6 crore in the same quarter last year. The company's total revenue from operations also saw a decline of 11.51%, reaching ₹7,546.4 crore, compared to ₹8,528.4 crore a year ago. However, Dr Reddy's experienced growth in its Indian market, with generics revenue rising by 20% to ₹1,566.3 crore, and a 14% increase in Europe, reaching ₹1,452 crore. The company's total expenses increased to ₹7,826.7 crore in Q4 FY26, up from ₹7,050.8 crore in the previous year. For the fiscal year 2025-26, the consolidated profit after tax was ₹4,157.6 crore, down from ₹5,725.2 crore in FY25, while total revenue rose to ₹33,700.2 crore from ₹32,643.9 crore. G V Prasad, Co-Chairman & MD, emphasized the need for cost efficiencies and portfolio optimization to strengthen the business. The board has proposed a final dividend of ₹8 per equity share, pending shareholder approval.